Research never ceased to continue in this field, and, more recently, in 2020, a prospective trial [27] on ABO(H) antigens conducted on 60 patients with oral cavity malignant and potentially malignant lesions, identified that the degree of loss of ABO(H) antigens in tissue specimens can be used as a marker of tumor stage of the patient. Here, ABO is linked to neoplasm.